Theralase(r) release's 4q2023 interim financial statements

Toronto, on / accesswire / march 27, 2024 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated photo dynamic compounds ("pdcs") for the safe and effective destruction of various cancers, bacteria and viruses has released the company's audited annual consolidated 2023 financial statements ("financial statements"). theralase® will be hosting a conference call on wednesday april 3rd, 2024 at 11:00 am et, which will include a presentation of the financial and operational results for the fiscal year ending december 31st , 2023.
CAN Ratings Summary
CAN Quant Ranking